DelveInsight Business Research LLP

DelveInsight’s “Isocitrate Dehydrogenase (IDH) Inhibitors- Market Insights, Epidemiology, and Market Forecast-2032”  report delivers an in-depth understanding of the Isocitrate Dehydrogenase (IDH) Inhibitors, historical and forecasted epidemiology as well as the Isocitrate Dehydrogenase (IDH) Inhibitors market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Isocitrate Dehydrogenase (IDH) Inhibitors market report provides current treatment practices, emerging drugs, Isocitrate Dehydrogenase (IDH) Inhibitors market share of the individual therapies, current and forecasted Isocitrate Dehydrogenase (IDH) Inhibitors market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Isocitrate Dehydrogenase (IDH) Inhibitors treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities. It assesses the underlying potential of the market.

Some of the key facts of  Isocitrate Dehydrogenase (IDH) Inhibitors Market Report:

• Enasidenib (Idhifa®) is an oral selectively allosteric inhibitor of IDH2 mutation developed by Celgene Corporation under a global exclusive license from Agios Pharmaceuticals. It shows more powerful inhibitory effects on IDH2 R172K rather than IDH1 R140Q (ORR, 53.3% vs. 35.4%; CR, 24.4% vs. 17.7%) mutation, although it has inhibitory effects on both the mutations. FDA approved enasidenib for the treatment of adult R/R AML with IDH2 mutations on 1 August 2017. The recommended oral dose is 100 mg once daily for at least 6 months or until disease progression or intolerable adverse reaction.

• Enasidenib could reduce the serum total 2-HG level by more than 90%, reverse abnormal epigenetic changes, and induce differentiation of mutant IDH2 AML cells both in vitro and in murine xenograft models. Furthermore, it shows no cytotoxicity. The results from a phase 1/2 clinical trial in adult R/R AML have shown that enasidenib monotherapy in adult R/R AML is efficacious and safe. When patients were administered oral enasidenib once daily for 28 days in a cycle, an overall response rate (ORR) was 40.3%. About 87.3% of the patients reached their first treatment response within 5.8 months. The total CR rate was 19.3% with a median overall survival (OS) of 9.3 months and a median effect-free survival of 6.4 months, moreover, patients who reached CR had a longer OS of 19.7 months. Enasidenib seemed to induce AML cell differentiation and showed no cytotoxicity. Treatment-emergent adverse events were mainly elevated bilirubin (81%), nausea (50%), and diarrhea (43%). decreased appetite (34%), and vomiting (34%).

Key Benefits of the Report:

• The report covers the descriptive overview of Isocitrate Dehydrogenase (IDH) Inhibitors, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies

• Comprehensive insight has been provided into the Isocitrate Dehydrogenase (IDH) Inhibitors epidemiology and treatment in the 7MM

• Additionally, an all-inclusive account of both the current and emerging therapies for Isocitrate Dehydrogenase (IDH) Inhibitors are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape

• A detailed review of Isocitrate Dehydrogenase (IDH) Inhibitors market; historical and forecasted is included in the report, covering drug outreach in the 7MM

• The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Isocitrate Dehydrogenase (IDH) Inhibitors market

Got queries? Click here to know more about the  Isocitrate Dehydrogenase (IDH) Inhibitors Market Landscape 

Isocitrate Dehydrogenase (IDH) Inhibitors Overview

Isocitrate dehydrogenase (IDH) is a key enzyme involved in the conversion of isocitrate to α-ketoglutarate (α-KG) in the tricarboxylic acid (TCA) cycle. IDH mutation produces a neomorphic enzyme, which can lead to the abnormal accumulation of R-2-HG and promotes leukemogenesis.

Isocitrate Dehydrogenase (IDH) Inhibitors Epidemiology Insights: 

• According to the World Allergy Organization (2016), in the International Study of Asthma and Allergies in Childhood (ISAAC), self-reported Isocitrate Dehydrogenase (IDH) Inhibitors (hay fever) prevalence in 13- to 14-yr-old children was 22.1% as a global total. It differs among regions: 23.7% in Latin America, 33.3% in North America, 12.3% in Northern & Eastern Europe, and 21.2% in Western Europe.  

• According to Centers for Disease Control and Prevention (2018), 19.2 million (7.6%) adults (18 and above) were diagnosed with hay fever, it was more prevalent in women (8.3%) than men (6.4%), while 5.2 million children (7.2%) were reported hay fever, it was more prevalent in boys (7.9%) than girls (6.4%).

Isocitrate Dehydrogenase (IDH) Inhibitors Epidemiological Segmentation 

• Isocitrate Dehydrogenase Inhibitors prevalent cases 

•  Isocitrate Dehydrogenase Inhibitors diagnosed cases 

• Isocitrate Dehydrogenase Inhibitors treatment cases 

Isocitrate Dehydrogenase Inhibitors Market Outlook 

The Isocitrate Dehydrogenase Inhibitors market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Isocitrate Dehydrogenase (IDH) Inhibitors market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand of better technology.

 This segment gives a thorough detail of Isocitrate Dehydrogenase (IDH) Inhibitors market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on an annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

 According to DelveInsight, Isocitrate Dehydrogenase (IDH) Inhibitors market in 7MM is expected to change in the study period 2019-2032.

 Learn more by requesting for sample @ Isocitrate Dehydrogenase (IDH) Inhibitors Market  Landscape

Table of Contents

1.  Key Insights 

2.  Report Introduction 

3.  Executive Summary of  Isocitrate Dehydrogenase (IDH) Inhibitors Market 

4.  Disease Background and Overview

5.  Epidemiology and patient population

6.  The United States 

7.  EU 5

8.  Isocitrate Dehydrogenase (IDH) Inhibitors Market  Emerging Therapies

9.  Isocitrate Dehydrogenase (IDH) Inhibitors Market Cancer Market Outlook

10.  Market Access and Reimbursement of Therapies

11.  Appendix

12.  Isocitrate Dehydrogenase (IDH) Inhibitors Market   Report Methodology

13.  DelveInsight Capabilities

14.  Disclaimer

15. About DelveInsight

Click here to read more about Isocitrate Dehydrogenase Inhibitors Market Landscape

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: +91 9568243403
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com